On November 1, 2017 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported that oral and poster presentations will be given with regard to emicizumab at The American Society of Hematology (ASH) (Free ASH Whitepaper) 2017 in Atlanta, Georgia, United States. Emicizumab is a bispecific antibody under development for hemophilia A (Press release, Chugai, NOV 1, 2017, View Source [SID1234521451]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data from additional six-month follow-up of global Phase lll studies in hemophilia A with inhibitors to factor VIII, HAVEN 1 study (NCT02622321) and HAVEN 2 study (NCT02795767), will be shown at the conference. The HAVEN 2 will be presented at 7:30 EST on December 9 as part of the official Press Program at ASH (Free ASH Whitepaper). Both studies have been conducted in collaboration with Roche and Genentech, while HAVEN 1 is for adults and adolescents and HAVEN 2 is for children.

In addition, preliminary data from HAVEN 4 study (NCT03020160), a Phase lll study with hemophilia A patients with or without inhibitors which examines emicizumab prophylaxis administered subcutaneously once every four weeks, and real-world data from a non-interventional trial in children under 12 years of ages with hemophilia A with inhibitors will be presented.